Oasmia Pharmaceutical AB Inside information Oasmia`s rights issue has been oversubscribed The preliminary result of the rights issue in Oasmia Pharmaceutical AB (publ) (`Oasmia` or the `Company`), in which the subscription period ended on 4 December 2019, amounts to 198,329,980 shares subscribed for in the rights issue with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. In addition, the Company has received applications to subscribe for 78,277,041 shares without subscription rights, corresponding to approximately 39.3 percent of the rights issue. Thus, the rights issue has been oversubscribed. `I am very pleased with the outcome in the rights issue,...
|
